Journal ArticleDOI
Management of gastric cancer in Asia: resource-stratified guidelines
Lin Shen,Yan Shen Shan,Huang Ming Hu,Timothy J. Price,Bhawna Sirohi,Kun-Huei Yeh,Yi-Hsin Yang,Takeshi Sano,Han-Kwang Yang,Xiaotian Zhang,Sook Ryun Park,Masashi Fujii,Yoon-Koo Kang,Li-Tzong Chen,Li-Tzong Chen +14 more
TLDR
This work aims to provide a stepwise strategy for management of gastric cancer applicable to different levels of health-care resources in Asian countries, using the categories of basic, limited, enhanced, and maximum level.Abstract:
Summary Gastric cancer is the fourth most common cancer globally, and is the second most common cause of death from cancer worldwide. About three-quarters of newly diagnosed cases in 2008 were from Asian countries. With a high mortality-to-incidence ratio, management of gastric cancer is challenging. We discuss evidence for optimum management of gastric cancer in aspects of screening and early detection, diagnosis, and staging; endoscopic and surgical intervention; and the concepts of perioperative, postoperative, and palliative chemotherapy and use of molecularly targeted therapy. Recommendations are formulated on the basis of the framework provided by the Breast Health Global Initiative, using the categories of basic, limited, enhanced, and maximum level. We aim to provide a stepwise strategy for management of gastric cancer applicable to different levels of health-care resources in Asian countries.read more
Citations
More filters
Journal ArticleDOI
Construction of a metabolomics profile of arsenic trioxide effect in gastric carcinoma cell line SGC7901
TL;DR: The metabolomics data from this study, in combination with previous transcriptomics and proteomics data, could serve as valuable resources for the understanding of the specific antitumor mechanism of ATO treatment.
Journal ArticleDOI
Multi-Modality Treatment for Patients With Metastatic Gastric Cancer: A Real-World Study in China.
TL;DR: Multi-modality treatments offer a survival benefit for patients with metastatic GC, and patients who received palliative gastrectomy or metastasectomy had a longer survival than those who only received intraperitoneal chemotherapy or radiotherapy.
Journal ArticleDOI
Pathological tumor infiltrative pattern and sites of initial recurrence in stage II/III gastric cancer: Propensity score matching analysis of a multi-institutional dataset.
Nobuhiko Nakagawa,Mitsuro Kanda,Seiji Ito,Yoshinari Mochizuki,Hitoshi Teramoto,Kiyoshi Ishigure,Toshifumi Murai,Takahiro Asada,Akiharu Ishiyama,Hidenobu Matsushita,Chie Tanaka,Daisuke Kobayashi,Michitaka Fujiwara,Kenta Murotani,Yasuhiro Kodera +14 more
TL;DR: The aim of this study was to evaluate the relationship between pathological infiltrative pattern (INF) and initial recurrence patterns in patients with stage II/III gastric cancer using a large multicenter database.
Journal ArticleDOI
Disparities in gastric cancer screening among people with disabilities: a national registry-linkage study in South Korea.
Youngjee Kim,Dong Wook Shin,Dong Wook Shin,Hyoung Woo Kim,Jin Hyung Jung,Kyungdo Han,In Young Cho,So Young Kim,So Young Kim,Kui Son Choi,Jong Heon Park,Jong Hyock Park,Jong Hyock Park,Ichiro Kawachi +13 more
TL;DR: In spite of the availability of national gastric cancer screening program, there are significant disparities in gastriccancer screening participation, especially among people with severe disabilities and those with renal failure or brain-related/mental disabilities.
Journal ArticleDOI
Is preoperative staging enough to guide lymph node dissection in clinically early gastric cancer
Jia Xu,Jia Xu,Hui Cao,Jun Young Yang,Yun Suhk Suh,Seong Ho Kong,Se Hyung Kim,Sang Gyun Kim,Hyuk Joon Lee,Woo Ho Kim,Han-Kwang Yang +10 more
TL;DR: Comprehensive evaluation based on MDCT, preoperative histological type, and tumor size is an effective method to predict lymph node metastasis (LNM) and guide tailored LN dissection for cEGC.
References
More filters
Journal ArticleDOI
Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008.
TL;DR: The results for 20 world regions are presented, summarizing the global patterns for the eight most common cancers, and striking differences in the patterns of cancer from region to region are observed.
Journal ArticleDOI
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial
Yung-Jue Bang,Eric Van Cutsem,A. Feyereislova,Hyun Cheol Chung,Lin Shen,Akira Sawaki,Florian Lordick,Atsushi Ohtsu,Yasushi Omuro,Taroh Satoh,G. Aprile,Evgeny Kulikov,Julie Hill,Michaela Lehle,Josef Rüschoff,Yoon-Koo Kang +15 more
TL;DR: Trastuzumab in combination with chemotherapy can be considered as a new standard option for patients with HER2-positive advanced gastric or gastro-oesophageal junction cancer.
Journal ArticleDOI
Perioperative Chemotherapy versus Surgery Alone for Resectable Gastroesophageal Cancer
David Cunningham,William H. Allum,Sally P. Stenning,Jeremy Thompson,Marianne Nicolson,J. Howard Scarffe,F. Lofts,Stephen Falk,Timothy Iveson,David Smith,Ruth E Langley,Monica Verma,Simon Weeden,Yu Jo Chua +13 more
TL;DR: In patients with operable gastric or lower esophageal adenocarcinomas, a perioperative regimen of ECF decreased tumor size and stage and significantly improved progression-free and overall survival.
Journal ArticleDOI
Management of Helicobacter pylori infection—the Maastricht IV/ Florence Consensus Report
Peter Malfertheiner,Francis Mégraud,John Atherton,Anthony T. R. Axon,Franco Bazzoli,Gian Franco Gensini,Javier P. Gisbert,David Y. Graham,Ernst J. Kuipers +8 more
TL;DR: In this 4th edition of the Maastricht consensus report aspects related to the clinical role of H pylori were looked at again in 2010, with recommendations to guide doctors involved in the management of this infection associated with various clinical conditions.
Journal ArticleDOI
Capecitabine and oxaliplatin for advanced esophagogastric cancer.
TL;DR: Capecitabine and oxaliplatin are as effective as fluorouracil and cisplatin, respectively, in patients with previously untreated esophagogastric cancer, in a two-by-two design.